#### **TITLE PAGE** 1

## 2 Title- A Phase 1 Study of Novel Antiplatelet Agent to Overcome Pharmacogenomic **Limitations of Clopidogrel**

#### Dr. Anil Pareek-MD<sup>1\*</sup>, Mr. Nitin Chandurkar-M.Pharm<sup>2</sup>, Mr.Vivek Raut-M.Pharm<sup>3</sup>, Mr. Kumar 4

5

3

## Naidu-M.Sc.<sup>4</sup>

#### 6 **Affiliations**

<sup>1\*</sup>President, Medical Affairs and Clinical Research, Ipca Laboratories Limited, Mumbai, 7 8 Maharashtra, India;

<sup>2</sup>Senior Vice President, Clinical Research & Development, Ipca Laboratories Limited, Mumbai, 9 Maharashtra, India; 10

<sup>3</sup>Deputy General Manager, Clinical Research & Development, Ipca Laboratories Limited, 11 12 Mumbai, Maharashtra, India;

<sup>4</sup>Assistant General Manager, Clinical Data Management and Statistical Analysis, Ipca 13 Laboratories Limited, Mumbai, Maharashtra, India. 14

Short Title- Antiplatelet Drug Overcoming Clopidogrel's Limitations 15

Total Word Count: 4911 16

17

18

## 20 Address for correspondence

- 21 Name: Dr. Anil Pareek
- 22 **Email:** anil.pareek@ipca.com
- 23 Address: President–Medical Affairs and Clinical Research, Ipca Laboratories Limited, 142 AB,
- 24 Kandivali Industrial Estate, Kandivali West, Mumbai 400067
- 25 **Contact:** +91-22-66474641
- **Fax:** +91-22-28686954
- 27 **ORCID ID:** 0000-0002-5048-1629
- 28
- 29
- -
- 30
- 31

# A PHASE 1 STUDY OF NOVEL ANTIPLATELET AGENT TO OVERCOME PHARMACOGENOMIC LIMITATIONS OF CLOPIDOGREL

## 35 Abstract

Background: Clopidogrel is the most commonly prescribed thienopyridine as part of dual antiplatelet therapy for the treatment of cardiovascular diseases. However, Clopidogrel responsiveness shows variability based on CYP2C19 polymorphism. Therefore, we planned a study with an objective of evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of a novel thienopyridine antiplatelet agent AT-10 in healthy Indian subjects in comparison with standard dosage regimen of Clopidogrel based on their CYP2C19 genotyping.

<u>Methods:</u> Two CYP2C19 genotype based groups were identified i.e., Poor Metabolizer and Extensive Metabolizers with 20 subjects in each group (N=40) for participating in a randomized, two period, cross-over study. Each study period lasted 6 days including administration of loading and maintenance doses of AT-10 (40mg/10mg) or Clopidogrel (300mg/75mg). The pharmacokinetics and pharmacodynamics were assessed on day 1 and day 6 at several time intervals.

Results: Overall result of pharmacodynamic parameters showed that, mean % Inhibition of Platelet Aggregation between AT-10 and Clopidogrel in all subjects at Post-dose 6hr (loading dose) (AT-10: Clopidogrel; 73.30% vs. 18.53%) and Post-dose 6 hr on Day 6 (maintenance dose) (AT-10: Clopidogrel; 83.41% vs. 51.19 %) obtained from the AT-10 group was significantly higher than the Clopidogrel group. Further, %inhibition of platelet aggregation from AT-10 treatment in poor metabolizer group was significantly higher than the Clopidogrel treatments in extensive metabolizer group.

- 55 Overall pharmacokinetic comparison in all subjects indicates that AT-10 gives greater exposure
- to active Metabolite MP-H4 than Clopidogrel.
- 57 <u>Conclusion:</u> AT-10 may emerge as a promising anti-platelet drug and can be further developed in
- 58 clinical studies for the unmet medical needs of cardiovascular diseases.
- 59 CTRI Registration: CTRI/2021/03/032206

#### 60 Clinical Perspectives

- AT-10 (2-oxo-Clopidogrel) is a novel thienopyridine P2Y12 inhibitor under clinical development in India.
- It is a Clopidogrel derivative that is metabolically converted to produce the active thiol
   metabolite similar to Clopidogrel.
- The response to AT-10 was found unaffected by genetic CYP2C19 polymorphisms to the
   extent of its influence in Clopidogrel, thus eliminating the need for characterization of
   Clopidogrel responsiveness and thereby maintaining effectiveness in all patients,
   including those patients who are identified as CYP2C19 poor and intermediate
   metabolizers.
- Further studies are required to investigate the influence of CYP2C19 functional
   polymorphisms on the response to AT-10 dose in diverse clinical settings, and especially
   on the risk of recurrent thrombotic events during AT-10 treatment as compared to
   Clopidogrel therapy.
- Keywords: Antiplatelet agent, AT-10, Clopidogrel, CYP2C19 genotype, Pharmacodynamics,
  Pharmacokinetics

## 76 Abbreviations

- 77 ACS- Acute Coronary Syndrome
- 78 ADP- Adenosine Diphosphate
- 79 AUC- Area under the curve
- 80 BMI- Body Mass Index
- 81 CAD- Coronary Artery Disease
- 82 CDSCO- Central Drug Standard Control Organization
- 83 CES-1- Carboxylesterase-1
- 84 CVD- Cardiovascular Disease
- 85 CYP- Cytochrome P
- 86 DES- Drug Eluting Stent
- 87 EM-Extensive Metabolizers
- 88 IM- Intermediate Metabolizers
- 89 LCMS/MS- Liquid Chromatography-Mass Spectrometry
- 90 LOF- Loss of Function
- 91 LSMs- Least-squares means
- 92 PCI- Percutaneous Coronary Intervention

- 93 PD- Pharmacodynamic
- 94 PK- Pharmacokinetic
- 95 PM- Poor Metabolizers
- 96 TEAE- Treatment Emergent Adverse Events
- 97 USFDA- United States Drug and Food Administration

98			
99			
100			
101			

## 103 INTRODUCTION

104 Cardiovascular diseases remain the leading cause of mortality worldwide. Estimated 20.5 million deaths were reported globally due to cardiac conditions in 2021 which showed a marked increase 105 from 12.1 million CVD deaths recorded in  $1990^{1}$ . Of these deaths, more than 50% are secondary 106 107 to coronary artery disease, with acute coronary syndrome (ACS) accounting for approximately 10% of all admissions presenting to emergency care physicians<sup>2</sup>. Platelets play a key role in the 108 development of ACS, as plaque rupture is followed by platelet adhesion, activation, and 109 aggregation, leading to thrombosis formation<sup>3</sup>. Antiplatelet drugs serve as a first-line 110 antithrombotic therapy for the management of acute ischemic events and the prevention of 111 secondary complications in vascular diseases. Numerous antiplatelet therapies have been 112 developed; however, currently available agents are still associated with inadequate efficacy, risk 113 of bleeding, and variability in individual response<sup>4</sup>. Dual Antiplatelet therapy with Aspirin and 114 115 P2Y12 inhibitors, drugs from thienopyridine class (Ticlopidine, Clopidogrel, and Prasugrel) is therefore the cornerstone of medical management in patients with ACS, those undergoing 116 percutaneous coronary Intervention (PCI), prevention of stent thrombosis and is necessary in 117 both the acute phase and long-term maintenance therapy 5-7. Despite these benefits, many patients 118 continue to have recurrent atherothrombotic events while receiving standard dual antiplatelet 119 therapy<sup>8</sup>. Amongst all P2Y12 inhibitors, Clopidogrel is the most commonly prescribed 120 thienopyridine with acceptable safety profile. However, the pharmacodynamic response to 121 Clopidogrel varies widely from subject to subject, and about 25% of patients treated with 122 standard Clopidogrel doses display low ex vivo inhibition of ADP-induced platelet aggregation<sup>9</sup>. 123 124 While the use of Clopidogrel has undoubtedly been a beneficial advance in the treatment of ACS

with regard to both short and long term morbidity and mortality<sup>10, 11</sup>, it remains a treatment with
several shortcomings.

Clopidogrel is a prodrug and its clinical efficacy appears to be a function of the amount of 127 enzymatically derived active thiol metabolite formed. Clopidogrel is first metabolized to the 128 intermediate metabolite, 2-oxo-Clopidogrel, followed by metabolism to an active thiol 129 metabolite in vivo. Notably, both metabolic steps leading to thiol formation have been shown to 130 be predominantly dependent on CYP2C19 and, to a lesser extent, CYP3A4. As a prodrug, 131 around 85% of Clopidogrel in vivo is inactivated by carboxylesterase-1 (CES-1) and the 132 remaining 15% is converted to the active metabolite H4 via a two-step process in liver, which is 133 134 predominantly influenced by cytochrome CYP2C19 polymorphisms. Various CYP enzymes are involved for converting Clopidogrel to its active metabolite (H4). First metabolic step is 135 predominantly dependent on CYP2C19 (45%) and second step on CYP3A4 enzyme (40%). 136 137 However, involvement of CYP2C19 during second step is only 21%. Since CYP2C19 is involved in both metabolic steps, any changes in its activity will have significant impacts on the 138 formation of the active thiol metabolite and hence, on the response to treatment<sup>12,13</sup>. The 139 metabolism of Clopidogrel to its active metabolite can be impaired by genetic variations in 140 CYP2C19 or by drugs that inhibit CYP2C19, such as Omeprazole or Esomeprazole. 141

142 It has been established that not all of the patients receiving Clopidogrel benefit to the same 143 extent, and it has been shown that patients with a Poor Metabolizers (PM) genotype status for 144 CYP2C19 are at increased risk of ischemic events after percutaneous coronary intervention <sup>5,14</sup> 145 suggesting that CYP2C19 polymorphism is a clinically relevant determinant of response to 146 Clopidogrel. In 2010, the USFDA had imposed a box warning on Clopidogrel bisulfate tablets 147 (Plavix) stating that "Effectiveness of Clopidogrel bisulfate depends on conversion to an active

148 metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 enzyme. Consider use 149 of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers" <sup>15</sup>. It 150 means there is a well-established relationship exists between CYP2C19 deficient 151 pharmacogenomic populations and Clopidogrel drug response that result in diminished 152 effectiveness in PMs because of impaired metabolism of Clopidogrel.

153

Patients with carriers of reduced-function CYP2C19 alleles (poor and intermediate metabolizers) will produce lower levels of Clopidogrel's active thiol metabolite. Due to which such patients shows diminished platelet inhibition, and are at higher risk of major adverse cardiovascular events, including a threefold greater risk of stent thrombosis <sup>16,17,18</sup> hence newer antiplatelet are preferred in such patients. Although, the newer agents like Prasugrel and Ticagrelor are devoid of such problems (genetic polymorphism) the CV benefits comes with cost of increased bleeding risk that includes fatal intracranial hemorrhage<sup>19</sup>.

161

There is a considerable heterogeneity observed in the activity of CYP450 enzymes in humans and it has become apparent that individuals have polymorphisms in CYP2C19 resulting in low or non responsiveness to Clopidogrel known as 'Clopidogrel resistance' <sup>16,20</sup>. The frequency of CYP2C19\*2 allele associated with PM type reported to be 47.23% in Coronary Artery Disease (CAD) patients in general population in India<sup>21</sup>. Studies conducted by Adithan et. al<sup>22</sup> have reported incidence of CYP2C19 polymorphism of around 37.9% in south Indian general population and 35.5% by Kavita et al<sup>23</sup> in western Indian general population.

170 In the recently published real-world data composing East Asians who had undergone Drug Eluting Stent (DES) implantation and received Clopidogrel based antiplatelet therapy indicated 171 that, Intermediate Metabolizers (IM) or PMs (PM) which was close to 62.1% of the total 172 population evaluated had a higher risk of cardiac death, myocardial infarction, and stent 173 thrombosis at 5-year follow-up compared with normal metabolizers<sup>24</sup>. Further, authors have also 174 reported that the risk of cardiac death, myocardial infarction and stent thrombosis in IMs and 175 PMs was much higher within 1 year after DES implantation. The most common CYP2C19 loss 176 of function allele is \*2 with allele frequencies of ~15% in Caucasians and Africans, and 29-35% 177 178 in Asians. These data indicates that the prevalence of IM and PM is more in Asian population than that of the western population <sup>18,24</sup>. This high prevalence of CYP2C19 polymorphism 179 renders Clopidogrel ineffective or adds variability in effectiveness in poor and intermediate 180 181 metabolizers respectively.

182

Hence, to overcome the shortcomings of Clopidogrel associated mainly with CYP2C19 183 metabolism, we have developed a novel antiplatelet agent AT-10 (2-oxo-clopidogrel), which is a 184 Clopidogrel derivative that is metabolically converted in one CYP-dependent step, to produce 185 186 the active metabolite similar to the approved listed drug Plavix (Clopidogrel bisulfate tablet). A major advantage of the prodrug AT-10 is its more efficient metabolism through one CYP-187 dependent step, as compared to the two-step process for Clopidogrel involving several CYP450 188 189 isoenzymes. The metabolic pathway of Clopidogrel and AT-10 (2-oxo-clopidogrel) is depicted in Figure 1. 190

191 The response to AT-10 may not be influenced by genetic CYP2C19 polymorphisms to the extent192 of its influence in Clopidogrel, thus eliminating the need for characterization of Clopidogrel

193 responsiveness and thereby maintaining effectiveness in all patients, including those patients who are identified as CYP2C19 poor and intermediate metabolizers. Prior to this Indian Phase 1 194 study, one proof of concept clinical study was performed with an objective of evaluating and 195 196 establishing the dose-response relationship of single and multiple doses of AT-10 ranging from 7.5 to 40 mg in healthy human subjects. In that proof of concept study, AT-10, 40-mg dose was 197 198 found to be comparable to the Clopidogrel 300 mg dose with regard to %IPA at 6 hr following the single loading dose. Hence, AT-10 40 mg was selected as the loading dose. Since the 199 maintenance dose of Clopidogrel (75 mg) is <sup>1</sup>/<sub>4</sub>th of the loading dose of Clopidogrel (300 mg), 200 201 AT-10 10-mg (<sup>1</sup>/<sub>4</sub>th of the loading dose of AT-10 40-mg) was selected as the maintenance dose to administer in this Phase 1 Indian study. AT-10 was found to be safe and well tolerated in humans 202 at all doses tested in that proof of concept study. So, in light of promising data obtained from 203 nonclinical and earlier conducted proof of concept clinical study, we first time evaluated safety, 204 tolerability, pharmacodynamics and pharmacokinetics of AT-10 in healthy Indian subjects in 205 comparison with standard dosage regimen of Clopidogrel. It is important to note that AT-10 is an 206 intermediate metabolite in the metabolic pathway of Clopidogrel to the active metabolite. 207 208 Therefore, this study does not represent the first exposure of AT-10 in humans. It does, however, 209 represent the direct administration of AT-10 to humans.

210 METHODS

#### 211 Study Design

This was an open label, unicentric, randomized, two-period, two-sequence, crossover, comparative, single and multiple-dose, Pharmacokinetic (PK) and Pharmacodynamic (PD) study conducted in healthy human subjects. Two CYP2C19 genotype based groups were identified i.e., PM (PM) and EMs (EM) with 20 subjects in each group (N=40). Each metabolizer group was

216 further randomized in 1:1 ratio to receive either Clopidogrel (Plavix, Sanofi Aventis, USA) or AT-10 (Ipca Laboratories Limited, India) in 2 sequences. Sequence 1 includes administration of 217 AT-10 on 1<sup>st</sup> period and Clopidogrel on 2<sup>nd</sup> period while sequence 2 was the reversal of sequence 218 219 1. All subjects underwent a 2 period treatment regimen; each period treatment lasted for 6 days. A study period included administration of loading dose (LD) of Clopidogrel 300 mg or AT-10, 220 40 mg on Day 1 followed by once daily maintenance dose (MD) of either Clopidogrel 75 mg or 221 AT-10, 10 mg from day 2 to day 6. Then the subjects were crossed over to receive the alternate 222 therapy for the 2<sup>nd</sup> period. A wash out period of at least 14 days was maintained between the 223 study periods. 224

On day 1, all subjects fasted for at least 10 hours prior dosing and at least 4 hours post dose in each period. Water was restricted prior to 1 hour of study drug administration and 1 hour post dosing in each period. All subjects were housed in the clinical facility from at least 11 hours prior dosing until at least 24 hours post dosing after administration of last MD in each period.

#### 229 Study Population

230 Healthy Indian adult male and female subjects of age between 18 to 45 years with body mass index (BMI) of 18.50 to 29.90 kg/m<sup>2</sup> were enrolled in the study. Prior enrollment, we conducted 231 CYP2C19 genotyping for categorizing the subjects as EMs (EM; genotype \*1/\*1) or PMs (PM; 232 genotype \*2/\*2). In order to confirm and cross verify the detected genotypes, the blood samples 233 of all screened subjects were assessed independently at two different laboratories. Subjects with 234 matching alleles only at both the testing laboratories were considered for enrollment in the study 235 provided that such subjects meet the study enrollment criteria. Polymerase Chain Reaction 236 (PCR) followed by DNA sequence analysis technology was used for genotyping test. Subjects 237

with no evidence of underlying disease, medical history, clinical examination and laboratory
investigations performed during the pre-study screening within 28 days prior to commencement
of the study were included.

Subjects with known allergy to Clopidogrel, AT-10 or any component of the formulation and to 241 any other related class of drug; history or presence of significant cardiovascular, respiratory, 242 hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, 243 musculoskeletal, neurological or psychiatric disease; history or presence of significant alcohol 244 dependence (abuse) or drug abuse within the past 1 year; history of chronic smoking or chronic 245 consumption of tobacco products; history of difficulty in donating blood and subjects with 246 247 known increased risks of bleeding were excluded from the study. Also, Subjects who had donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 248 days or > 200 ml within 90 days prior to first dose of study medication were excluded. Subjects 249 250 who had consumed any medication known to alter hepatic metabolic enzyme activity within 28 days prior to the initial dose of study medication (e.g. strong CYP3A inhibitors or inducers, 251 252 Omeprazole or other proton pump inhibitors) were excluded. Also, Pregnant or lactating women were not included in the study. 253

#### 254 **Ethics**

The study was done in accordance with the ethical principles of Declaration of Helsinki and requirements of Good Clinical Practice. It was approved by Sangini Hospital Ethics Committee and Indian Regulatory Authority [Central Drug Standard Control Organization (CDSCO)]. It was registered on Clinical Trials Registry India with registration number CTRI/2021/03/032206 [Registered on: 23/03/2021]. Written informed consent was obtained from all the participants'

prior participation in the study. No study related procedure was undertaken prior to obtainingwritten informed consent from subject.

#### 262 Safety Assessment

Safety assessments were performed by the investigator at screening and continued throughout the course of the study. Safety evaluations involved assessment of adverse events, coagulation parameters (PT and PTT), pre-dose and post-dose vital signs, ECGs, clinical laboratory testing (hematology, blood chemistry, and urinalysis), and general physical and clinical examinations. Coagulation parameters were also assessed at screening, at housing during each period, at 8 hrs post-dose on each dosing day and at exit or early termination.

#### 269 Pharmacodynamic Assessment

270 Pharmacodynamic (PD) assessment i.e. inhibition of platelet aggregation was performed by 271 using ADP-induced platelet aggregation from whole blood treated with sodium citrate (3.2%) as an anti-coagulant. The whole blood impedance aggregometry (CHRONO-LOG<sup>®</sup> 592, 272 Pennsylvania, United States) was used for assessing ADP-induced platelet aggregation. It uses 273 274 electrical impedance to measure platelet aggregates in response to agonist addition in whole blood. As a result, electrical resistance between the wires increase and this change in impedance 275 is recorded continuously in AGGRO/LINK<sup>®</sup>-WBA software. This change in electrical 276 impedance is directly proportional to the extent of platelet aggregation and is indicated on the 277 278 digital display in ohms (unit) after six minutes. The inhibition of platelet aggregation was further calculated by using the formula: Platelet Inhibition (%IPA) = (1 - Residual Impedance 279 280 (amplitude in ohm) / Baseline Impendence (amplitude in ohm))  $\times$  100. The PD samples were analyzed at the clinical site only. Aggregometry was carried-out after stimulation of collected 281

blood sample with 20  $\mu$ M of ADP. As compared to conventional Light Transmission Aggregometry (LTA), the impedance aggregometry assesses platelet function under more physiological conditions as it is performed in whole blood, thus enabling other blood elements to influence platelet aggregation. Also, it takes place on a solid surface resembling the physiological process of platelet adhesion and aggregation. The principle of impedance method is similar to that of LTA except that it is done in whole blood, thus obviating the need for preparation of a platelet rich and poor plasma which may add variability to the test results.

For pharmacodynamic assessment, blood samples were collected into pre-labeled Citrate Tubes (3.2%). A total of 4 blood samples (2.7 mL each) were collected, prior administration of drug and at 30 minutes, 2 and 6 hours after the study drug administration on each dosing day. Additionally, one more blood sample was collected on day 7 after 24 hours of last MD administration in each period.

#### 294 Pharmacokinetic Assessment

In each period, blood samples (5 mL each) were collected in pre-labelled Na-Citrate vacutainers at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h after study drug administration on Days 1 and 6 for assessment of PK parameters. In between on Day 3, 4 and 5 of each period, pre-dose sample was also collected.

Plasma concentrations of derivatized active metabolite H4 (measured as MP-H4) were determined using a validated Liquid Chromatography-Mass Spectrometry (LCMS/MS) method. The PK analysis was performed using a model independent software program (WinNonlin Professional version 8.3). Maximum concentration ( $C_{max}$ ), and the time to reach Cmax i.e.,  $T_{max}$ were obtained from plasma concentration time curves. Then elimination rate constant (k),

elimination half life ( $t^{1/2}$ ), Clearance (Cl), Volume of distribution ( $V_d$ ) and Area under the curve (AUC) were calculated following non-compartmental analysis of plasma time course data for active metabolite MP-H4.

#### 307 Statistical Analysis

For PD analyses, %IPA generated by Aggregometry at different time points among the groups were assessed. Maximum %IPA for each group was compared using Analyses of variance (ANOVA) with sequence, treatment, period and subject (sequence) as fixed effects. For the comparison between types of metabolizers, the ANOVA model with types of metabolizers as fixed effect was used. Least-squares means (LSMs) with 95% CI was calculated by ANOVA for each comparison.

To estimate the PK parameters, statistical comparison of the overall PK (Day 1 and Day 6), single-dose and multiple-dose PK parameters of peak (Cmax) and total (AUCt, AUCinf) exposure of MP-H4 were made between the AT-10 and Clopidogrel dose groups; between and within metabolizer groups. Geometric means were calculated for Cmax, AUCt and AUCinf. ANOVA was performed on the ln-transformed PK parameters Cmax, AUCt and AUCinf. Geometric means and its 90% CI were given for all parameters in each phenotype.

Data were presented using descriptive statistics i.e. n (%) for categorical variables and mean, SD, minimum and maximum for continuous variables. according to the regulatory guidelines. Significance was calculated using P values; p <0.05 was considered statistically significant. All the statistical analyses were performed using SAS version 9.4.

#### 325 **RESULTS**

#### 326 Subject enrollment and Demographics characteristics

A total of 40 subjects were enrolled in the study. Two CYP2C19 genotype based groups were identified i.e., PM and EMs with 20 subjects in each group. Out of 40 enrolled subjects, 37 subjects had completed the study. Remaining 3 subjects were discontinued from the study due to adverse event (n=2) and consent withdrawal (n=1). The two treatment groups were well balanced with regards to all baseline characteristics. Demographic characteristics of these subjects are given in **Table 1**.

#### 333 Pharmacodynamic Results

The ADP induced platelet aggregation was assessed for change from baseline in each treatment group at each time point assessed on each dosing day for PD analysis. The inhibition of ADPinduced platelet aggregation occurred rapidly, reaches peak at around 6 hr and inhibition was sustained until 24hr post dose. The mean %IPA over 6 days of drug administration (loading and maintenance dose) is shown in **Figure 2** for both AT-10 and Clopidogrel.

339 The mean %IPA between PMs and EMs in AT-10 group showed that, %IPA at Post-dose 6 hr on 340 day 6 (MD) obtained from the AT-10 in EMs group appeared to be higher than the AT-10 treatments in PMs group. However, the difference between the AT-10 treatments in EMs versus 341 AT-10 treatments in PMs was found to be statistically insignificant at post dose 6 hr LD and post 342 343 dose 24 hr after day 6 (MD). The mean % IPA was found to be comparable in poor and EMs in 344 AT-10 group. It means AT-10 produces equivalent PD effect in both extensive and PMs and the 345 antiplatelet effect of AT-10 is not affected by the genotyping metabolizing status of the 346 volunteers. Although %IPA post 6 hr on day 6 was significant, it was more than 70% in PMs.

That should be enough to be efficient. This indicates that the PD response to AT-10 may not be influenced by CYP2C19 polymorphisms in PMs (**Table 2**).

On the contrary, following loading and maintenance dose post 6 hr on Day 6 in Clopidogrel treatment group the mean %IPA was found to be significantly higher for EMs as compared to PMs. In PMs, %IPA observed was half of that observed in EM. This indicates that the PD response to Clopidogrel following loading and maintenance dose is influenced by CYP2C19 polymorphisms resulting in less PD effect in PMs than that in EMs which is consistence with data reported for Clopidogrel in various studies<sup>25,26</sup>. (**Table 2**)

355 Further, when we compared the mean %IPA between AT-10 PMs and Clopidogrel EMs, the %IPA at Post-dose 6hr (LD) obtained from the AT -10 treatment in PM group was statistically 356 357 significant with that of Clopidogrel treatments in EMs group. However, %IPA at Post-dose 6 hr on Day 6 (MD) and Post-dose 24 hr after Day 6 obtained from the AT-10 treatment in PM group 358 appears to be statistically insignificant than the Clopidogrel treatments in EMs group. This 359 360 indicates that the response to AT-10 is not influenced by CYP2C19 polymorphisms, hence patients including those who are CYP2C19 Poor Metabolizers, may receive clinical benefits 361 from AT-10 treatment (Table 3). 362

Moreover, the overall result of PD parameters showed that, mean %IPA between AT-10 and Clopidogrel in all subjects at Post-dose 6hr (LD), Post-dose 6 hr on Day 6 and Post-dose 24 hr after Day 6 obtained from the AT-10 group was significantly higher than the Clopidogrel group. Similarly, following loading and maintenance dose, the mean %IPA for AT-10 treatment group was significantly higher than that observed with Clopidogrel treatment group in both poor and EMs (**Figure 2**).

#### 369 **Pharmacokinetic Results**

AT-10 is a Clopidogrel derivative that is metabolically converted to produce the active metabolite (MP-H4) of the approved listed drug Plavix (Clopidogrel bisulfate). The PK parameters for MP-H4 for all subjects have been presented in **Table 4** after administration of AT-10 and Clopidogrel.

Analysis of MP-H4 between AT-10 and Clopidogrel in all subjects at Day 6 showed that, Cmax 374 375 (AT-10: Clopidogrel; 2.68 ng/mL Vs 1.07 ng/mL p = 0.0001) and AUCt (AT-10 : Clopidogrel; 3.27 hr\*ng/mL Vs 1.09 hr\*ng/mL p = 0.0000) of pharmacologically active metabolite MP-H4 376 377 are significantly higher in AT-10 treatment than Clopidogrel indicates that AT-10 at 10mg gives greater exposure of MP-H4 metabolite than Clopidogrel 75mg. MP-H4 metabolite is responsible 378 379 for pharmacological and therapeutic action; hence pharmacodynamic effect (anti-platelet effect) expected at steady state with AT-10 treatment can be greater than Clopidogrel treatment 380 regardless of genotyping status. The mean plasma concentration curve after administration of 381 loading and maintenance dose of AT-10 and Clopidogrel is shown in Figure 3. 382

Overall, there is a statistically significant difference observed between AT-10 and Clopidogrel treatment for assessed pharmacokinetic parameters. This indicates that 40mg LD and 10mg MD of AT-10 gives greater exposure of H4 (measured as MP-H4) metabolite than Clopidogrel 300 mg loading and 75mg maintenance dose.

#### 387 Safety assessment

All enrolled subjects were eligible for safety analysis. Treatment emergent adverse events (TEAE) occurred during the study are summarized in **Table 5**. A total of 11 TEAEs were observed in 7 participants where 5 AEs were mild, 1 AE was moderate and 5 AEs were severe. Nine of these events were possibly related and 2 were unlikely related to the study drug. No serious adverse events were reported during the course of study. Hence, both the treatments were found to be safe and well tolerated in all study population despite the differences in their genotyping status.

#### 395 **DISCUSSION**

Despite of newer antiplatelet agents (P2Y12 inhibitors), Clopidogrel is the most widely prescribed thienopyridine with acceptable safety profile; however has major shortcoming associated with CYP2C19 genetic polymorphism. After more than a decade following the introduction of dual antiplatelet therapy as the standard of care in the setting of ACS and PCI<sup>11,27</sup> significant concerns with the effectiveness of Clopidogrel were raised, mainly nonresponsiveness to therapeutic effects resulting from CYP polymorphisms<sup>28,29</sup>.

402 To overcome the limitations of Clopidogrel associated with CYP2C19 metabolism, Ipca has developed a novel antiplatelet drug AT-10, that is metabolically converted to produce the active 403 404 metabolite of the approved listed drug Plavix (Clopidogrel bisulfate). A major advantage of the AT-10 is its more efficient metabolism as compared to the two-step process for Clopidogrel 405 involving several CYP450 isoenzymes. This study is the first to evaluate the PD, PK, safety and 406 tolerability of AT-10 in Indian subjects. We have also emphasized the effect of a person's CYP 407 genotype on pharmacological profiles of AT-10 (test drug) and Clopidogrel (reference drug) as 408 previously published studies have shown impact of CYP2C19 polymorphism on Clopidogrel 409 responsiveness up to a major extent <sup>16,25,30,31</sup>. 410

This study met its primary objective and showed that AT-10 is safe and well-tolerated when administered as LD of 40mg followed by 10mg MD for 5 consecutive days. Safety findings from all enrolled subjects did not show any clinically significant trends or abnormalities in liver
function tests, clinical chemistry, hematology, and coagulation. Most of the AEs were relatively
minor in nature and were considered possibly and unlikely related to study drug treatment.
Results from vital signs and ECGs were unremarkable. The overall number of subjects with
TEAEs was similar in two treatment groups. No bleeding or other signs of bleeding were
reported in the subjects for both the treatments.

Following loading and maintenance dose, the mean %IPA for AT-10 treatment group was significantly higher than that observed with Clopidogrel treatment group in overall study population, poor and EMs. It means AT-10 produces higher platelet inhibition than the Clopidogrel following loading and maintenance doses not only in EMs but also in PMs. Hence AT-10 is likely to benefit all patients irrespective of their genotyping status.

The single and multiple dose pharmacokinetics of active metabolite (H4) have been assessed. 424 From the PK data it was observed that, in overall population for MP-H4 the concentration and 425 426 extent of exposure (Cmax and AUC) following loading and maintenance dose are significantly higher in AT-10 treatment group than Clopidogrel treatment. Similarly, in both extensive and 427 PMs the concentration and extent of exposure (Cmax and AUC) following loading and 428 maintenance dose are significantly higher in AT-10 treatment group than Clopidogrel treatment 429 430 for MP-H4. It means the pharmacokinetics of Clopidogrel is influenced by genetic CYP2C19 431 polymorphisms to a greater extent than its influence in AT-10 treatment group. As per the published literature<sup>32</sup> a strong correlation between H4 plasma exposure and platelet inhibition 432 exists, demonstrating that individuals with highest exposure to H4 active metabolite have the 433 434 greatest antiplatelet response. Since H4 metabolite of Clopidogrel is responsible for

pharmacological and therapeutic action the pharmacodynamics effect expected with AT-10treatment may be greater than Clopidogrel treatment in both CYP2C19 EMs and PMs.

The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-437 Extended Antiplatelet Monotherapy) Extended study had compared the outcomes of Aspirin 438 monotherapy with those of Clopidogrel monotherapy after PCI<sup>33</sup>. Total of 5438 patients who 439 were maintained on DAPT without clinical events for  $12\pm6$  months after percutaneous coronary 440 intervention with drug-eluting stents were enrolled. During an extended follow-up of more than 5 441 years after randomization, Clopidogrel monotherapy (75mg) compared with Aspirin 442 monotherapy (100mg) was associated with lower rates of the composite net clinical outcome 443 444 (death, nonfatal myocardial infarction, stroke, readmission attributable to acute coronary syndrome, and bleeding) in patients without clinical events for  $12\pm 6$  months after percutaneous 445 coronary intervention with drug-eluting stents. 12.8 Vs 16.9% (hazard ratio, 0.74 [95% CI, 0.63-446 447 0.86]; P<0.001).

As per the recently published Guideline for the Management of Patients With Chronic Coronary Disease by American Heart Association/American College of Cardiology Joint Committee, in patients with Chronic Coronary Disease (CCD) treated with PCI, DAPT consisting of Aspirin and Clopidogrel for 6 months post PCI followed by single antiplatelet therapy is indicated to reduce MACE and bleeding events<sup>34</sup>.

These findings and clinical practice guidelines again supports the use of Clopidogrel as the preferred antiplatelet agent over Aspirin for the secondary prevention of coronary artery disease. It means Clopidogrel has a place in therapy so as AT-10 as it overcomes the shortcomings of Clopidogrel associated mainly with CYP2C19 polymorphism.

As concluded by Jean-Sébastien Hulot et al<sup>26</sup> in their pharmacogenetic study, this study results also shows that the CYP2C19\*2 mutant allele is a major genetic determinant of the pharmacodynamic response to standard-dose Clopidogrel (75 mg/day) in healthy human subjects. As per Drug Label Information of Plavix<sup>15</sup>, Clopidogrel 75mg per day has shown average platelet inhibition of 40% to 60% at steady state but several clinical trials have shown variability in response to inhibition of platelets and are generally around 30% which was also observed in our study.

It is of due importance that CYP2C19 remains the predictor of variability in response of 464 Clopidogrel and has been clearly evident in previous clinical evaluations<sup>25,26</sup>. Similar 465 466 observations were also seen in our study as EMs have shown IPA in range of 37% to 71% while participants with CYP2C19 LOF alleles representing PMs have shown very poor inhibition of 467 platelets maximum up to 36% only but for AT-10, the platelet inhibition was consistent despite 468 469 the disparities in phenotypes of the participants. There was no detrimental impact of CYP2C19 polymorphism on %IPA of AT-10. This indicates that AT-10 can be used in all patients without 470 concerning about the type of metabolizer as compared to selective use of Clopidogrel due to 471 'Clopidogrel resistance'. Being a Clopidogrel derivative, AT-10 can provide all benefits of 472 Clopidogrel and at the same time will overcome the shortcomings of Clopidogrel. It can be a 473 safer alternative to newer agents being similar to Clopidogrel. Further it may replace Clopidogrel 474 475 in the management of cerebrovascular diseases (transient ischemic attack and Stroke) and peripheral vascular diseases. 476

Since the concentration and extent of exposure ( $C_{max}$  and AUC) of active metabolite (H4) and the observed mean %IPA following loading and maintenance dose are significantly higher in AT-10 treatment group than Clopidogrel treatment in both EMs and PMs, there is a need to optimize the

dose of AT-10 in target population. Further studies can be planned to assess and find out the PD
equivalent dose of AT-10 when administered as a loading and maintenance dose.

#### 482 Limitations of Investigation

This was a healthy volunteer study with limited sample size. The interventions in the study were evaluated in poor and extensive metabolizers. Effects of AT-10 need further evaluation in intermediate, rapid and ultra rapid metabolizers whose prevalence is significant in general patient population.

Although inhibition of platelet aggregation is recognized as surrogate marker for incidence of
MACE (i.e. higher % inhibition correlates to lesser CV events.), it is still unknown what level of
%IPA translates in preventing CV events.

Hence, further larger studies are required to investigate the influence of CYP2C19 functional
polymorphisms on the response to AT-10 dose in the clinical setting, and especially on the risk
of recurrent thrombotic events during AT-10 treatment including bleeding risk as compared to
Clopidogrel therapy.

#### 494 CONCLUSION

Based on the results of our study, it could be concluded that AT-10 may emerge as a promising anti-platelet drug and can be further developed in clinical studies for the unmet medical needs of cardiovascular diseases. This might be studied alone or as a part of dual antiplatelet therapy for implementation into future treatment strategies.

499

501 **Funding:** This study was funded by Ipca Laboratories Limited.

#### 502 **Disclosures:**

503 Dr. Anil Pareek is the President of Medical Affairs and Clinical Research Department in the

504 pharmaceutical Industry, Ipca Laboratories Limited.

505 Mr. Nitin Chandurkar is the Senior Vice President of Clinical Research and Development in
506 the pharmaceutical Industry, Ipca Laboratories Limited.

507 Mr. Vivek Raut is currently the Deputy General Manager in Clinical Research and
508 Development department at Ipca Laboratories Limited.

509 Mr. Kumar Naidu is Assistant General Manager in Clinical Data Management and Statistical
510 Analysis at Ipca Laboratories Limited.

511 All authors are employees of Ipca Laboratories Ltd and involved in conceptualization, 512 coordination and execution of the study.

#### 513 Acknowledgements:

Authors acknowledge CBCC Global Research LLP, Neuberg Supratech Laboratory & Research Institute Pvt. Ltd., geneOmbio Technologies Pvt. Ltd. and Cliantha Research for their extended support in conducting laboratory assessments. Authors appreciate the help of Dr. Baishakhee Bishoyi, employee of Ipca Laboratories for drafting this manuscript; Mangesh Manchekar and Tushar Jadhao, employees of Ipca Laboratories Limited, for their help in labelling and packaging of clinical trial supplies.

## 521 **REFERENCES**

522	1.	Lindstrom M, DeCleene N, Dorsey H, Fuster V, Johnson CO, LeGrand KE, et al.
523		Global burden of cardiovascular diseases and risks collaboration, 1990-2021. J Am
524		Coll Cardiol. 2022;80(25):2372–425.
525		
526	2.	Kontos MC, Diercks DB, Kirk JD. Emergency department and office-based
527		evaluation of patients with chest pain. Mayo Clin Proc. 2010;85(3):284–99.
528		
529	3.	Libby P. Current concepts of the pathogenesis of the acute coronary syndromes.
530		Circulation. 2001;104(3):365–72.
531		
532	4.	Xiang Q, Pang X, Liu Z, Yang G, Tao W, Pei Q, et al. Progress in the development of
533		antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic.
534		Pharmacol Ther. 2019;203(107393):107393.
535		
536	5.	Menozzi A, Lina D, Conte G, Mantovani F, Ardissino D. Antiplatelet therapy in acute
537		coronary syndromes. Expert Opin Pharmacother. 2012;13(1):27-42.
538		

539	6.	Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC
540		Guidelines for the management of acute coronary syndromes. Eur Heart J Acute
541		Cardiovasc Care. 2023;44(38):3720-826.
542		
543	7.	Steinhubl SR, Berger PB, Mann JT III, Fry ETA, DeLago A, Wilmer C, et al. Early
544		and sustained dual oral antiplatelet therapy following percutaneous coronary
545		intervention: A randomized controlled trial. JAMA. 2002;288(19):2411.
546		
547	8.	Effects of Clopidogrel in addition to aspirin in patients with acute coronary
548		syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
549		
550	9.	Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting:
551		Response variability, drug resistance, and the effect of pretreatment platelet
552		reactivity. Circulation. 2003;107(23):2908-13.
553		
554	10.	Sabatine MS, Cannon CP, Gibson CM. Addition of Clopidogrel to aspirin and
555		fibrinolytic therapy for myocardial infarction with ST-segment elevation. ACC Curr J
556		Rev. 2005;14(6):1.
557		

558	11.	Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of
559		Clopidogrel in addition to aspirin in patients with acute coronary syndromes without
560		ST-segment elevation. N Engl J Med. 2001;345(7):494–502.
561		
562	12.	Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al.
563		Identification of the human cytochrome P450 enzymes involved in the two oxidative
564		steps in the bioactivation of Clopidogrel to its pharmacologically active metabolite.
565		Drug Metab Dispos. 2010;38(1):92–9.
566		
567	13.	Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics.
568		2010;20(7):463–5.
569		
570	14.	Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al.
571		Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic
572		events in patients with acute myocardial infarction. Circulation. 2004;109(25):3171-
573		5.
574		
575	15.	Accessdata.fda.gov [Internet]. 1997. PLAVIX® (Clopidogrel bisulfate) tablets, for
576		oral use. Available from:
577		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/009768s053lbl.pdf

579	16.	Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome
580		P-450 polymorphisms and response to Clopidogrel. N Engl J Med. 2009;360(4):354-
581		62.
582		
583		
584		
585	17.	Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al.
586		Genetic determinants of response to Clopidogrel and cardiovascular events. N Engl J
587		Med. 2009;360(4):363–75.
588		
589	18.	Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation
590		Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for
591		CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther.
592		2013;94(3):317-23.
593		
594	19.	Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al.
595		Ticagrelor versus Clopidogrel in patients with acute coronary syndromes. N Engl J
596		Med. 2009;361(11):1045–57.
597		

598	20.	Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, et al. Clarifying			
599		the importance of CYP2C19 and PON1 in the mechanism of Clopidogrel			
600		bioactivation and in vivo antiplatelet response. Eur Heart J. 2012;33(22):2856–2464a.			
601					
602	21.	Shetkar SS, Ramakrishnan S, Seth S, Chandna P, Verma SK, Bhargava B, et al. CYP			
603		450 2C19 polymorphisms in Indian patients with coronary artery disease. Indian			
604		Heart J. 2014;66(1):16–24.			
605					
606	22.	Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R.			
607		Allele and genotype frequency of CYP2C19 in a Tamilian population. Br J Clin			
608		Pharmacol. 2003;56(3):331–3.			
609					
610	23.	Shalia KK, Shah VK, Pawar P, Divekar SS, Payannavar S. Polymorphisms of MDR1,			
611		CYP2C19 and P2Y12 genes in Indian population: Effects on Clopidogrel response.			
612		Indian Heart J. 2013;65(2):158–67.			
613					
614	24.	Lee SH, Jeong YH, Hong D, Choi KH, Lee JM, Park TK, et al. Clinical impact of			
615		CYP2C19 genotype on Clopidogrel-based antiplatelet therapy after percutaneous			
616		coronary intervention. JACC Cardiovasc Interv. 2023;16(7):829-43.			

618	25.	Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al.
619		Association of cytochrome P450 2C19 genotype with the antiplatelet effect and
620		clinical efficacy of Clopidogrel therapy. JAMA. 2009;302(8):849-57.
621		
622	26.	Hulot JS. Cytochrome P450 2C19 loss-of-function polymorphism is a major
623		determinant of Clopidogrel responsiveness in healthy subjects. Blood.
624		2006;108(7):2244–7.
625		
626	27.	Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, et al.
627		Effects of pretreatment with Clopidogrel and aspirin followed by long-term therapy in
628		patients undergoing percutaneous coronary intervention: the PCI-CURE study.
629		Lancet. 2001;358(9281):527–33.
630		
631	28.	Amin AM, Sheau Chin L, Mohamed Noor DA, Mostafa H, Abdul Kader MASK, Kah
632		Hay Y, et al. The effect of CYP2C19 genetic polymorphism and non-genetic factors
633		on Clopidogrel platelets inhibition in East Asian coronary artery disease patients.
634		Thromb Res. 2017;158:22–4.
635		
636	29.	Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS II, et al. Common
637		polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and

	pharmacodynamic response to Clopidogrel but not prasugrel. J Thromb Haemost.
	2007;5(12):2429–36.
30.	Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450
	2C19 polymorphism in young patients treated with Clopidogrel after myocardial
	infarction: a cohort study. Lancet. 2009;373(9660):309-17.
31.	Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting:
	response variability, drug resistance, and the effect of pretreatment platelet reactivity:
	Response variability, drug resistance, and the effect of pretreatment platelet
	reactivity. Circulation. 2003;107(23):2908-13.
32.	Karaźniewicz-Łada M, Danielak D, Burchardt P, Kruszyna Ł, Komosa A, Lesiak M,
	et al. Clinical pharmacokinetics of Clopidogrel and its metabolites in patients with
	cardiovascular diseases. Clin Pharmacokinet. 2014;53(2):155-64.
33.	Kang J, Park KW, Lee H, Hwang D, Yang HM, Rha SW, et al. Aspirin versus
	Clopidogrel for long-term maintenance monotherapy after percutaneous coronary
	intervention: The HOST-EXAM extended study. Circulation. 2023;147(2):108–17.
	31.

- 658 34. Virani, Salim S., et al. "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the
- 659 management of patients with chronic coronary disease: a report of the American
- 660 Heart Association/American College of Cardiology Joint Committee on Clinical
- 661 Practice Guidelines." Circulation 148.9 (2023): e9-e119.
- 662

	Treatment Sequence			
Characteristic	Sequence AB	Sequence BA	Overall	P- Value
	(N=20)	(N=20)	(N=40)	
Gender, n (%)				
Female	6 (30.0)	6 (30.0)	12 (30.0)	0.9999
Male	14 (70.0)	14 (70.0)	28 (70.0)	
Age (years), Mean $\pm$ SD	$32.6\pm6.36$	$34.9 \pm 5.21$	$33.7\pm5.85$	0.2185
BMI (Kg/m^2), Mean $\pm$ SD	$23.41 \pm 3.47$	$24.51 \pm 2.67$	$23.96 \pm 3.11$	0.2691
Height (cm), Mean ± SD	$166.2\pm10.20$	$162.0\pm7.23$	$164.1 \pm 8.99$	0.1413
Weight (Kg), Mean ± SD	$64.91 \pm 12.67$	$64.08 \pm 9.07$	$64.50 \pm 10.89$	0.8119
Race, n (%)				
Asian	20 (100)	20 (100)	40 (100)	0.9999
Menopause Status, n (%)				
Not Menopausal	6 (30.0)	6 (30.0)	12 (30.0)	0.9999
Menstrual Cycle, n (%)				
Regular and Clinically Normal	6 (30.0)	6 (30.0)	12 (30.0)	0.9999
N: The number of subjects in th	e safety populatio	n for each sequen	ce or the safety r	opulation for

## **Table 1: Demographic and baseline characteristics of the enrolled subjects**

N: The number of subjects in the safety population for each sequence or the safety population for the overall; n: The number of subjects in the specific category. %: calculated using the number of subjects in the safety population for each sequence, or the safety population for the overall, as denominator (n/N\*100)

Age, Height, weight and BMI at Pre-Screening visit are considered.

Treatment A : AT-10 (2-oxo-Clopidogrel bisulfate) Tablets 40 mg/10mg

Treatment B : Plavix® (Clopidogrel bisulfate) Tablets 300 mg/75mg

664

665

666

667

668

669

Time point	Extensive Metabolizers	Poor Metabolizers	95% CI of LS mean difference	P value
AT-10				
Post-dose 6hr (LD)	80.694 ± 27.5592	$65.905 \pm 30.2122$	14.79 (-3.72 - 33.30)	0.1141
Post-dose 6hr on Day 6 (MD)	$94.269 \pm 12.9226$	$72.558 \pm 40.9339$	21.71 (1.74 - 41.68)	0.0340
Post-dose 24hr after Day 6 (MD)	$88.995 \pm 21.1644$	$79.032 \pm 34.8512$	9.96 (-9.16 - 29.09)	0.2975
Clopidogrel				
Post-dose 6hr (LD)	$37.140 \pm 50.8991$	$-1.168 \pm 46.1272$	38.31 (4.84 - 71.78)	0.0262
Post-dose 6hr on Day 6 (MD)	$71.551 \pm 29.9885$	$30.833 \pm 42.7628$	40.72 (15.70 - 65.74)	0.0022
Post-dose 24hr after Day 6 (MD)	$65.306 \pm 58.5336$	$36.644 \pm 46.0291$	28.66 (-5.98 - 63.31)	0.1020
Data Presented as Me	ean± SD; LD- Loading	g Dose; MD-Maintenai	nce Dose	

## Table 2: Mean %IPA between Poor and Extensive Metabolizers in AT10 and Clopidogrel

672

## 673 Table 3: Statistical Analysis of Mean %IPA between AT-10 Poor Metabolizers and

## 674 Clopidogrel Extensive Metabolizers

Time point	AT - 10	Clopidogrel	95% CI of LS mean	P	
1		1 0	difference	value	
Post-dose 6hr (LD)	65.905 ± 30.2122	$37.140 \pm 50.8991$	28.765 (6.11 - 51.42)	0.0389	
	30.2122	30.8991			
Post-dose 6hr on Day 6	$72.558 \pm$	$71.551 \pm$	1.007 (-19.02% -21.03%)	0.9328	
(MD)	40.9339	29.9885	1.007 (-17.0270 -21.0570)	0.7520	
Post-dose 24hr after	$79.032 \pm$	$65.306 \pm$	13.72643 (-13.23% -	0.3954	
Day 6 (MD)	34.8512	58.5336	40.68%)	0.3934	
Data Presented as Mean± SD; LD- Loading Dose; MD-Maintenance Dose					

675

676

677

678

Parameters	Day1	(N=37)	Day6	(N=37)		
Parameters	AT-10	Clopidogrel	AT-10	Clopidogrel		
$C_{max}(ng/mI)$	$9.56\pm7.01$	$4.31\pm4.06$	$3.01 \pm 1.58$	$1.22 \pm 0.64$		
Cmax(ng/mL)	(73.33%)	(94.30%)	(52.35%)	(52.51%)		
#Tmax (hr)	0.50	0.75	0.50	0.50		
#Tmax (hr)	(0.25 - 2.00)	(0.25 - 2.00)	(0.00 - 4.00)	(0.50 - 1.00)		
AUCt	$14.23\pm4.82$	$4.80\pm2.43$	$3.42 \pm 1.03$	$1.23\pm0.62$		
(hr* ng/mL)	(33.84%)	(50.57%)	(30.26%)	(50.52%)		
AUCinf	$15.36\pm4.41$	$5.34\pm2.36$	$3.81 \pm 1.12$	$1.44 \pm 0.63$		
(hr*ng/mL)	(28.68%)	(44.12%)	(29.41%)	(43.75%)		
T1((hr))	$3.33 \pm 1.85$	$0.91\pm0.43$	$1.76 \pm 2.29$	$0.71\pm0.55$		
T <sup>1</sup> /2 ( hr )	(55.50%)	(47.30%)	(130.15%)	(77.74%)		
$V_{ol}(1/h_r)$	$0.27\pm0.13$	$0.87\pm0.27$	$0.69\pm0.40$	$1.27\pm0.50$		
Kel ( 1/hr )	(49.06%)	(31.08%)	(57.85%)	(39.56%)		
Kel_lower	$3.16 \pm 1.77$	$1.54\pm0.67$	$1.84 \pm 1.03$	$0.98\pm0.23$		
Kel_lowel	(56.00%)	(43.42%)	(56.24%)	(23.01%)		
Kal uppar	$11.03\pm4.51$	$4.21 \pm 1.14$	$4.57 \pm 1.58$	$2.25\pm0.62$		
Kel_upper	(40.92%)	(27.04%)	(34.50%)	(27.49%)		
	$2796782.26 \pm$	$68069565.39 \pm$	$2914055.03 \pm$	$61932416.51 \pm$		
Vd/F (mL)	720716.15	31035114.97	1169552.58	26502532.12		
	(25.77%)	(45.59%)	(40.13%)	(42.79%)		
	$13282418.32 \pm$	$84001569.64 \pm$	$6254732.88 \pm$	$63098668.98 \pm$		
Cl/F (mL/hr)	7752256.80	42699043.41	6181797.33	57845349.30		
	(58.36%)	(50.83%)	(98.83%)	(91.67%)		
Data Presented a	s Mean $\pm$ SD (CV	%)				
<sup>#</sup> For T <sub>max</sub> mediar	<sup>#</sup> For T <sub>max</sub> median (min – max)					

# 680 Table 4: Pharmacokinetic Parameters of MP-H4 on Day 1 and Day 6 (All subjects)

681

System Organ Class	Treatment A	Treatment B	Overall		
Preferred Term	(N = 40)	(N = 39)	(N = 40)		
Gastrointestinal Disorders	2 (0.9) 2	3 (1.3) 3	5 (12.5) 5		
Nausea	2 (0.9) 2	3 (1.3) 3	5 (12.5) 5		
General Disorders And Administration Site	00.0 (00.0)	1 (0.4) 3	1 (2.5) 3		
Conditions					
Pain	00.0 (00.0)	1 (0.4) 1	1 (2.5) 1		
Pyrexia	00.0 (00.0)	1 (0.4) 1	1 (2.5) 1		
Swelling	00.0 (00.0)	1 (0.4) 1	1 (2.5) 1		
Psychiatric Disorders	1 (0.4) 1	00.0 (00.0)	1 (2.5) 1		
Anxiety	1 (0.4) 1	00.0 (00.0)	1 (2.5) 1		
Respiratory, Thoracic And Mediastinal Disorders	1 (0.4) 1	00.0 (00.0)	1 (2.5) 1		
Cough	1 (0.4) 1	00.0 (00.0)	1 (2.5) 1		
Skin And Subcutaneous Tissue Disorders	00.0 (00.0)	1 (0.4) 1	1 (2.5) 1		
Erythema	00.0 (00.0)	1 (0.4) 1	1 (2.5) 1		
MedDRA version 24.1.					

## 683Table 5: Summary of Treatment Emergent Adverse Events

Data presented as n (%) E

E: Number of events; N: Number of subjects dosed with each treatment; n: Number of subjects with adverse event with particular category; %: Calculated using the number of subjects treated with each treatment as the denominator (n/N\*100).

Treatment A: AT-10 (2-oxo-Clopidogrel bisulfate) Tablets 40 mg/10mg

Treatment B: Plavix® (Clopidogrel bisulfate) Tablets 300 mg/75mg

684

# 692 Fig.1: Metabolic Pathway of Clopidogrel and AT-10 (2-Oxo-Clopidogrel)

693			
694			
695			
696			
697			
698			
699			
700			
701			
702			
703			

# 704 Fig.2: Overall %IPA of AT-10 vs. Clopidogrel

705			
706			
707			
708			
709			
710			
711			
712			
713			

# Fig 3: MP-H4 of AT-10 and Clopidogrel on Day 1 and Day 6 (Overall subjects)

715

716









